Synedgen Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
24
- Latest Deal Type
-
Later Stage VC
- Investors
-
5
Synedgen General Information
Description
Developer of polysaccharide-based drugs designed to enhance and mimic the innate immune system. The company's drugs target the complex interactions at the cell surface and mucosal interface to suppress inflammation, reduce infection, and improve healing at surfaces, enabling physicians to deliver improved quality of life for their patients with diseases of the gastrointestinal tract and pulmonary tree.
Contact Information
Website
www.synedgen.comCorporate Office
- 1420 North Claremont Boulevard
- Suite 105 D
- Claremont, CA 91711
- United States
Corporate Office
- 1420 North Claremont Boulevard
- Suite 105 D
- Claremont, CA 91711
- United States
Synedgen Timeline
Synedgen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 17. Later Stage VC | 01-Jul-2026 | Completed | Generating Revenue | |||
| 16. Secondary Transaction - Private | 01-Jun-2026 | Completed | Generating Revenue | |||
| 15. Debt - General | 01-Oct-2024 | Completed | Generating Revenue | |||
| 14. Grant | 17-Oct-2021 | Completed | Generating Revenue | |||
| 13. Debt - PPP | 28-Apr-2020 | Completed | Generating Revenue | |||
| 12. Later Stage VC | 29-Jan-2020 | Completed | Generating Revenue | |||
| 11. Grant | 13-Dec-2019 | Completed | Generating Revenue | |||
| 10. Grant | 30-Sep-2019 | Completed | Generating Revenue | |||
| 9. Later Stage VC | 11-Sep-2017 | $6M | $23.1M | Completed | Generating Revenue | |
| 8. Debt - General | 07-Nov-2016 | $3M | $17.1M | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Synedgen Patents
Synedgen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025232101-A1 | Compositions and methods of their use | Pending | 08-Mar-2024 | ||
| WO-2025189143-A1 | Compositions and methods of their use | Pending | 08-Mar-2024 | ||
| WO-2025189143-A8 | Compositions and methods of their use | Pending | 08-Mar-2024 | ||
| AU-2020444897-A1 | Compositions and methods of use thereof | Pending | 30-Apr-2020 | ||
| EP-4142740-A1 | Compositions and methods of use thereof | Pending | 30-Apr-2020 | A61K31/726 |
Synedgen Signals
Synedgen Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| HMC INQ | Venture Capital | Minority | ||
| StoryHouse Ventures | Venture Capital | Minority | ||
| United States Army Medical Research Acquisition Activity (USAMRAA) | Government | |||
| National Institutes of Health | Government | |||
| United States Department of War | Government |
Synedgen FAQs
-
When was Synedgen founded?
Synedgen was founded in 2009.
-
Where is Synedgen headquartered?
Synedgen is headquartered in Claremont, CA.
-
What is the size of Synedgen?
Synedgen has 24 total employees.
-
What industry is Synedgen in?
Synedgen’s primary industry is Drug Discovery.
-
Is Synedgen a private or public company?
Synedgen is a Private company.
-
What is Synedgen’s current revenue?
The current revenue for Synedgen is .
-
How much funding has Synedgen raised over time?
Synedgen has raised $27.4M.
-
Who are Synedgen’s investors?
HMC INQ, StoryHouse Ventures, United States Army Medical Research Acquisition Activity (USAMRAA), National Institutes of Health, and United States Department of War have invested in Synedgen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process